Our Resources

Patient-reported outcomes are crucial components of every clinical trial—and they’re stronger and more accurate when captured electronically. Here’s what you need to know about PROs and ePROs.

A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.

A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.

Medical device company, Mi-Helper, Inc., needed to find participants with a specific type of migraine. This required a long run-in period and mitigation to reduce the risk of drop-off before participants reached active treatment. In addition, Mi-Helper needed to ensure participants used the at-home device properly.

A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

Our APAC partnership with Oracle Life Sciences has been a huge success. Now, we're going global.

AI, patient advocacy groups, digital health technologies, and more. Here’s everything you need to know about the clinical trial trends of 2024—and how they’re reshaping the industry.